ABLYNX'S PARTNER BOEHRINGER INGELHEIM INITIATES PHASE I STUDY WITH NANOBODY TO TREAT ALZHEIMER'S DISEASE
(Thomson Reuters ONE) -
GHENT, Belgium, 29 October 2013 - Ablynx [Euronext Brussels: ABLX] today
announced that its partner Boehringer Ingelheim has dosed the first healthy
volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody®
for the treatment of Alzheimer's disease. The start of the Phase I study
triggers a milestone payment of ?5 million to Ablynx.
The Phase I study involves a single-centre, partially randomised, single-blind,
placebo-controlled trial to assess the safety, tolerability, pharmacokinetics
and pharmacodynamics of single ascending doses of intravenous and subcutaneous
injections with the Nanobody in healthy subjects. The trial is expected to
recruit 80 healthy volunteers and results are anticipated during H2 2014.
Dr Edwin Moses, Chairman and CEO of Ablynx commented:
"We are very pleased that Boehringer Ingelheim has dosed the first healthy
volunteers as part of our collaboration in Alzheimer's disease which we started
in 2007. The Nanobody's progress into the clinic demonstrates their belief in
its potential as a valuable treatment option for patients suffering from this
complex disease for which no adequate drugs are currently available. It is the
second of Ablynx's partnered programmes that has entered clinical development
this year and further enhances our pipeline which now contains seven Nanobody
products at clinical development stage."
In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research
and licensing agreement to discover and develop new therapies for Alzheimer's
disease using Ablynx's Nanobodies against a single disease target. The
collaboration has a potential value of $265 million in upfront and milestone
payments plus undisclosed royalties on product sales. Boehringer Ingelheim is
solely responsible for the development, manufacturing and commercialisation of
any products resulting from the collaboration.
About Alzheimer's disease
Alzheimer's disease is a neurodegenerative disease of the brain which leads to
loss of memory and cognitive functions. It is the most common form of dementia
in adults. It is estimated that 35.6 million people worldwide were living with
dementia in 2010. With the global population aging, this number is expected to
triple by 2050. Marketed products address some of the symptoms of the disease
but there remains a high unmet medical need as there are currently no treatments
available that delay or halt the progression of the disease.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
press release in pdf:
http://hugin.info/137912/R/1738649/583260.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1738649]
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 310075
Anzahl Zeichen: 4970
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX'S PARTNER BOEHRINGER INGELHEIM INITIATES PHASE I STUDY WITH NANOBODY TO TREAT ALZHEIMER'S DISEASE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
